At this year’s Pharmapack Europe held at Paris Expo, Porte de Versailles in Paris, SHL will be featuring Molly® 2.25, the much talked-about high volume auto injector, as well as Molly® C, a newly developed product related to connectivity.
The Molly® 2.25 is SHL’s first high volume auto injector with its design based on the original 1 ml Molly®; it was created to meet the increasing need for simple delivery of larger doses. With improved features, the pre-configured device will be extremely attractive to customers who are looking for top-quality products with quick development timelines and reduced costs.
Derived from SHL’s connectivity-based program—Alubena™—for drug delivery, the Molly® C is a disposable auto injector with a reusable recording unit which tracks and saves injection data. This concept was created to improve patient adherence, which has long been a problem in the healthcare industry. With Molly® “C”, which stands for “connected device”, injection data can be better managed and stored with an app that is available for demonstration at the SHL booth.
These two new products is a clear indication that SHL is constantly keeping a focused and innovative approach to advanced drug delivery, developing products that reflect market needs.
Both Molly® 2.25 and Molly® C will be available for demonstration at the SHL booth in the upcoming Pharmapack event. For further details, please visit us at Booth 736, Hall 5.2.
SHL is one of the world’s largest solution providers in design, development and manufacturing of advanced drug delivery devices such as auto injectors and pen injectors. With locations in Taiwan, Sweden and the US, our experienced engineers and designers develop product enhancements and breakthrough drug delivery solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
With over 3,500 staff worldwide, our organization consists of several distinct group companies:
SHL Medical Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
SHL Healthcare Develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
For additional information visit www.shl-group.com or contact us at email@example.com